Hinge Health prices IPO at $32, the top end of expected range

Hinge Health priced its IPO at $32 per share, the high end of its expected range, raising $273 million and valuing the company at approximately $2.6 billion, significantly below its $6.2 billion private valuation in 2021. The digital physical therapy company's IPO, trading under "HNGE" on the NYSE, is notable given the slowdown in digital health IPOs since 2021, though recent tech IPOs and strong earnings reports indicate a potential market recovery; Hinge reported Q1 revenue growth of 50% to $123.8 million and a net income of $17.1 million, a substantial improvement from the prior year's loss.

Analysis

Hinge Health priced its Initial Public Offering at $32 per share, the upper limit of its projected $28-$32 range, raising approximately $273 million for the company through the sale of 8.52 million shares. This IPO values the digital physical therapy provider at approximately $2.6 billion, a significant reduction from its $6.2 billion private market valuation in October 2021, indicating a substantial market recalibration for growth-stage companies. Trading under the ticker "HNGE" on the NYSE, Hinge Health demonstrated strong financial momentum in the first quarter, reporting a 50% year-over-year revenue increase to $123.8 million, up from $82.7 million, and a notable swing to profitability with a net income of $17.1 million, compared to a net loss of $26.5 million in the same period last year. This public offering is a key event for the digital health sector, which has seen minimal IPO activity since 2021 and faced headwinds from a post-Covid slowdown; however, recent positive developments in the broader tech IPO market, such as eToro's successful debut and CoreWeave's strong performance, may signal improving investor sentiment.

Key Decisions for Investors

• Investors should closely monitor Hinge Health's early trading performance and subsequent quarterly results to ascertain the sustainability of its Q1 profitability and robust revenue growth, especially given the considerable valuation reset from its last private funding round.
• The decreased IPO valuation compared to its 2021 private valuation might offer a more attractive entry point, but this must be weighed against the persistent challenges and recent underperformance within the broader digital health industry.
• Consider the company's ability to maintain its growth trajectory and positive earnings in a competitive market, particularly as the digital health sector navigates the normalization of demand post-pandemic.